Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
A recent study led by Dr. Connie Marras, clinician-scientist at the Krembil Research Institute at UHN, and Dr. Priti Gros, clinical fellow at Toronto Western Hospital, suggests that certain drugs used to treat prostate conditions may help to reduce men's risk of Parkinson's disease.
The researchers examined data from various provincial and federal databases to identify adult males who were prescribed drugs to treat prostate enlargement, a noncancerous condition that interferes with urination.
Between 1997 and 2019, 265,745 males in Ontario filled prescriptions for at least one of four drugs commonly used to treat prostate enlargement: terazosin, doxazosin, alfuzosin and tamsulosin. The first three of these drugs are known as phosphoglycerate kinase 1 (PGK1) activators, a class of drugs that improve the way cells manage energy.
"Previous research suggests that PGK1 activators have protective effects on the brain in experimental models of Parkinson's disease," explains Dr. Marras. "This may be because they improve the way that cells manage energy, and Parkinson's disease is associated with impaired energy management in brain cells.
"We wanted to know if continued use of these drugs is associated with fewer new cases of Parkinson's disease in the adult male population," Dr. Marras adds. "We also wanted to see if the effects of these drugs differ from that of tamsulosin, a non-PGK1 activator."
The researchers found that sustained use of all four drugs was associated with a lower risk of developing Parkinson's disease in men over the age of 66. PGK1 activators were associated with a six per cent reduction in disease incidence per year of use, and tamsulosin was associated with an eight per cent reduction per year of use.
"We found that regular use of PGK1 activators, as well as tamsulosin, was associated with reductions in the incidence of Parkinson's disease," says Dr. Marras.
"Further clinical studies are needed to determine how each of these drugs reduces an individual's risk for developing Parkinson's disease, and whether they may also be useful for treating the disease after it has developed."
This work was supported by ICES, the Bresler Family Research Fund and UHN Foundation.
Read more about the study.